Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
Neurogene (NGNE) Stock Price & Analysis
430 Followers
NGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.20 - $53.00
Previous Close$42.58
Volume249.27K
Average Volume (3M)112.50K
Market Cap
$552.70M
Enterprise Value$397.58M
Total Cash (Recent Filing)$169.53M
Total Debt (Recent Filing)$14.41M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 10, 2024EPS Estimate
-$1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.65
Shares Outstanding12,980,289
10 Day Avg. Volume116,576
30 Day Avg. Volume112,505
Standard Deviation0.29
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-9.01
Forecast
1Y Price Target
$56.67Price Target Upside23.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Neurogene News
PremiumCompany Announcements
Neurogene Releases Updated Corporate Presentation Online
PremiumCompany Announcements
Neurogene’s Rett Syndrome Trial Shows Promise
PremiumCompany Announcements
Neurogene’s NGN-401 Therapy Advances under FDA START ProgramBulls Say, Bears Say
Bulls Say
Competitive AdvantageNGN-401's differentiating features like a full MeCP2 transgene, ICV administration, and the EXACT self-regulatory element position it ahead of competition.
Earnings PotentialRett syndrome represents a $2.5B opportunity affecting 16,600–25,800 female patients, suitable for second-generation gene therapies.
Technological InnovationConsiderable value in the self-regulatory EXACT platform, which could broaden the scope of gene therapy to dosage-sensitive genetic disorders, such as Rett syndrome.
Bears Say
Clinical DataThe clinical data update on TSHA-102 was inconclusive, and this has impacted NGNE stock negatively.
Financial PerformanceR&D expenses for 1Q24 were above the analyst's estimate, indicating higher costs than expected.
Patient OutcomesThree of the four patients showed a worsening in their Rett Syndrome Behavior Questionnaire (RSBQ) score for at least one time point compared to baseline.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $12.20 and its highest was $53.00 in the past 12 months.
What is Neurogene’s market cap?
Currently, no data Available
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is May 10, 2024 which is 68 days ago.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Mar 18, 2024. The company reported $2.93 earnings per share for the quarter, beating the consensus estimate of -$1.173 by $4.103.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -$1.03.
How many shares outstanding does Neurogene have?
Neurogene has 12,980,289 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of $2.93 in its last earnings report, beating expectations of -$1.173. Following the earnings report the stock price went down -2.138%.
Which hedge fund is a major shareholder of Neurogene?
Among the largest hedge funds holding Neurogene’s share is Baker Bros Advisors LP. It holds Neurogene’s shares valued at 23M.
---
Neurogene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.67 (23.33% Upside)
$56.67 (23.33% Upside)
Blogger Sentiment
Bullish
NGNE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 48.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
153.45%
12-Months-Change
Fundamentals
Return on Equity
-30.96%
Trailing 12-Months
Asset Growth
98.41%
Trailing 12-Months
Company Description
Neurogene
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
---
NGNE Stock 12 Month Forecast
Average Price Target
$56.67
▲(23.33% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Ascendis Pharma
―
Crinetics Pharmaceuticals
―
Fate Therapeutics
―
Best Analysts Covering NGNE
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+40.50%
reiterated a buy rating 28 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +40.50% per trade.
---